This page collects WhisperX intelligence signals tagged #keytruda. It is designed for humans, search engines, and AI agents: each item links to a canonical source-backed record with sector, source, timestamp, credibility, and exportable structured data.
Merck is making a massive $6.7 billion strategic move to secure its oncology future, announcing its intent to acquire Terns Pharmaceuticals. The deal, priced at $53 per share, represents a 6% premium and targets Terns' crown jewel: the promising leukemia treatment TERN-701. This acquisition is a direct response to the ...
Merck is making a major strategic move to fortify its oncology portfolio, announcing its intent to acquire Terns Pharmaceuticals for $6.7 billion. The deal, priced at $53 per share, represents a 6% premium over Terns' recent closing price and centers on the promising leukemia drug TERN-701. Terns' stock had already sur...
Merck is making a massive $6.7 billion strategic move to acquire Terns Pharmaceuticals, a deal driven by the looming patent expiration of its blockbuster cancer drug, Keytruda. This acquisition is not merely an expansion; it's a critical hedge, granting Merck immediate access to Terns' promising pipeline of treatments ...
A high-stakes late-stage clinical trial for a promising kidney cancer treatment has failed, delivering a significant blow to the development programs of pharmaceutical giants Merck and Eisai. The Phase 3 LEAP-003 trial, which was testing a combination of Merck's blockbuster immunotherapy Keytruda (pembrolizumab) and Ei...